Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New combination treatment for hepatitis C reported more beneficial than standard therapy

27.09.2002


he New England Journal of Medicine’s Sept. 26 issue carries the first published report showing that a combination treatment with peginterferon alfa-2a (Pegasys) - a new long-acting interferon drug - and an antiviral medication is more beneficial than the standard combination therapy for people with the most-difficult-to-treat and most common strain of hepatitis C.



The large international study, headed by researchers at the University of North Carolina at Chapel Hill, is also the first published one to show that treatment with the investigational drug peginterferon alfa-2a in combination with the oral antiviral medication, ribavirin, is linked to a lower rate of troublesome side effects - depression, flu-like symptoms (chills, headache and fever) - than the standard interferon (Rebetron) and ribavirin.

"Sixty-five percent of patients in the study were infected with hepatitis C genotype 1, the most prevalent genotype we see here in the United States, and typically the least responsive to therapy," said study co-author Dr. Michael W. Fried, associate professor of medicine and director of clinical hepatology at the UNC School of Medicine.


"With this research, we’ve found the most significant evidence to date suggesting these patients might benefit by taking peginterferon alfa-2a in combination with ribavirin."

According to Fried, side effects of therapy can be very challenging for patients. "The study shows an approach that can offer patients superior efficacy without increases in some of the most common and difficult to tolerate adverse events associated with hepatitis C therapy."

Of the six different strains, or genotypes, of hepatitis C, approximately 70 percent of people in North America are infected with genotype 1.

The study was funded by Hoffmann-La Roche, the maker of Pegasys, and was conducted at 81 clinical sites in 18 countries. More than 1,100 patients were involved in one of three study arms: 453 were treated with peginterferon alfa-2a plus oral ribavirin, 224 with peginterferon alfa-2a plus placebo and 444 with interferon alfa-2b plus ribavirin. Patients were treated for 48 weeks and then monitored for an additional 24 weeks.

A key variable measured by the study was sustained viral response, defined as undetectable serum hepatitis C RNA after the treatment-free follow-up period.

Overall, patients treated with the peginterferon alfa-2a plus ribavirin combination achieved a 56 percent sustained response rate as compared to patients taking Rebetron (44 percent). Patients with genotype 1 had a sustained response rate of 46 percent, compared to patients on Rebetron (36 percent) and those on Pegasys plus placebo (21 percent).

A retrospective analysis of the data showed that response to PEG interferon alpha-2a plus ribavirin is predictable. At week 12, 86 percent of patients treated with PEG interferon demonstrated an early viral response; of these, 65 percent attained a sustained viral response. However, 97 percent of patients who did not respond by week 12 failed to achieve a sustained response.

"This means that physicians can create an alternate treatment plan for patients who do not show any response by week 12," said Fried. "And for those who do respond, it can be a motivation to continue to adhere to their treatment regimens."

Dr. Fried added that these treatment decisions must be individualized for each patient.

The hepatitis C virus is a life-threatening viral infection of the liver transmitted primarily through infected blood and blood products. Approximately 2.7 million Americans and 170 million people worldwide are chronically infected with the virus, which is often described as "silent" because people may be infected for 10 to 30 years and not exhibit symptoms, yet still be carrying the virus.

While many patients with the hepatitis C virus will not develop complications from their liver disease, chronic hepatitis C is still a leading cause of cirrhosis and liver cancer and is the major indication for liver transplants in this country.

The UNC Center for Liver Diseases and Transplantation provides highly specialized care for liver diseases for residents of North Carolina and surrounding regions. In addition to its commitment to patient care, the UNC liver program is dedicated to studying novel therapies for viral hepatitis, other chronic liver diseases and transplantation.


Contact note: Fried is available at (919) 966-8784 or mfried@med.unc.edu

Leslie Lang | EurekAlert!
Further information:
http://www.med.unc.edu/

More articles from Health and Medicine:

nachricht Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>